Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) SEC filings page provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, quarterly and annual reports, and other filings that describe material agreements, financial results, and key developments in Ultragenyx’s rare disease business.
Form 8-K filings for Ultragenyx often cover topics such as royalty purchase agreements, clinical and regulatory milestones, and financial updates. For example, the company has reported a Royalty Purchase Agreement with an OMERS investment vehicle involving a portion of future Crysvita royalty payments in the United States and Canada, including details on purchase price, royalty percentages, and caps based on multiples of the purchase price. Other 8-Ks summarize press releases announcing quarterly financial results, revenue by product, operating expenses, and net loss.
Ultragenyx also uses Form 8-K to report clinical and regulatory events, including initiation and progress of rolling Biologics License Application submissions for DTX401 in glycogen storage disease type Ia, longer-term Phase 3 data for DTX401, Breakthrough Therapy Designation for GTX-102 in Angelman syndrome, enrollment status of the Phase 3 Aspire study, and FDA communications such as a Complete Response Letter for UX111 in Sanfilippo syndrome type A. These filings outline requested chemistry, manufacturing, and controls information and the company’s plans to address regulatory feedback.
Through Stock Titan, users can review Ultragenyx’s SEC filings and benefit from AI-powered summaries that explain the significance of complex documents, including 10-K and 10-Q reports when available, as well as Form 4 insider transaction reports. Real-time updates from EDGAR combined with AI-generated insights help readers understand how material agreements, clinical data, and regulatory interactions influence Ultragenyx’s operations and capital structure in the rare and ultra-rare genetic disease space.
Ultragenyx (Nasdaq: RARE) filed an 8-K disclosing receipt of FDA Breakthrough Therapy Designation for GTX-102 (apazunersen) to treat Angelman syndrome.
The decision is supported by positive Phase 1/2 data in 74 children (ages 4-17) showing rapid, sustained and continuing developmental gains over up to three years.
Breakthrough status grants intensive FDA guidance, rolling review and potential priority review, which could materially shorten development timelines and lower regulatory risk.
The filing includes customary forward-looking statements covering clinical, regulatory and manufacturing uncertainties but announces no new financial terms.
Form 4 filing reveals insider trading activity at Ultragenyx Pharmaceutical (RARE) by Director Corazon (Corsee) D. Sanders. On June 20, 2025, Sanders executed a significant sale of company shares:
- Disposed of 2,405 shares at a price of $37.39 per share
- Transaction value: approximately $89,873
- Retained ownership: 15,344 shares held directly
This insider sale represents a notable reduction in Sanders' direct holdings in Ultragenyx. The transaction was executed as a standard sale (transaction code 'S') and was reported within the required SEC filing deadline. No derivative securities transactions were reported in this filing.
Ultragenyx Pharmaceutical Inc. (RARE) has filed a Form 144 with the U.S. Securities and Exchange Commission to notify the market of a proposed secondary sale of its equity.
- Securities: 2,405 shares of common stock
- Acquisition date & type: Restricted stock received on 05/15/2025 from the issuer
- Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004
- Planned sale date: Approximately 06/20/2025 on the NASDAQ exchange
- Estimated market value: US $89,922.95
- Total shares outstanding: 94,542,035 ⇒ proposed sale equals roughly 0.0025% of shares outstanding
- Prior 3-month sales: None reported
The filing is marked as LIVE and contains the standard representation that the seller is unaware of any undisclosed material adverse information. No additional financial data or strategic developments are included in this notice. Given the very small size of the transaction relative to Ultragenyx’s share base, the filing appears routine with limited market impact.